Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients
Status:
Terminated
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label Phase Ib dose escalation part followed by a randomized
double-blinded placebo controlled Phase II part.
The Phase Ib part will determine the Maximum Tolerated Dose (MTD)/Recommended Phase II Dose
(RP2D) of buparlisib in combination with docetaxel. Subsequently the MTD/RP2D will be
investigated in a Phase II randomized trial in patients with advanced or metastatic squamous
NSCLC.